JPWO2022043930A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022043930A5 JPWO2022043930A5 JP2023513510A JP2023513510A JPWO2022043930A5 JP WO2022043930 A5 JPWO2022043930 A5 JP WO2022043930A5 JP 2023513510 A JP2023513510 A JP 2023513510A JP 2023513510 A JP2023513510 A JP 2023513510A JP WO2022043930 A5 JPWO2022043930 A5 JP WO2022043930A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- patient
- treatment
- mdm2 antagonist
- skp2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims 32
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 claims 31
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 claims 31
- 201000011510 cancer Diseases 0.000 claims 31
- 239000005557 antagonist Substances 0.000 claims 30
- 230000014509 gene expression Effects 0.000 claims 19
- 102000000341 S-Phase Kinase-Associated Proteins Human genes 0.000 claims 17
- 108010055623 S-Phase Kinase-Associated Proteins Proteins 0.000 claims 17
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 238000000034 method Methods 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 13
- 239000000523 sample Substances 0.000 claims 13
- 239000012453 solvate Substances 0.000 claims 13
- 239000000090 biomarker Substances 0.000 claims 10
- 150000001204 N-oxides Chemical class 0.000 claims 9
- DRLCSJFKKILATL-YWCVFVGNSA-N 2-[(3r,5r,6s)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-3-methyl-1-[(2s)-3-methyl-1-propan-2-ylsulfonylbutan-2-yl]-2-oxopiperidin-3-yl]acetic acid Chemical compound C1([C@@H]2[C@H](N(C([C@@](C)(CC(O)=O)C2)=O)[C@H](CS(=O)(=O)C(C)C)C(C)C)C=2C=CC(Cl)=CC=2)=CC=CC(Cl)=C1 DRLCSJFKKILATL-YWCVFVGNSA-N 0.000 claims 6
- JDCHPEZNOKLHPK-KJEAJVGRSA-N (2S,3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1-(oxan-4-yl)propyl]-1-methoxy-3-oxoisoindol-2-yl]-2-methylpropanoic acid Chemical compound ClC1=CC=C(C=C1)[C@H]([C@@H](C(=O)O)C)N1[C@@](C2=C(C=C(C=C2C1=O)[C@](CC)(C1CCOCC1)O)F)(OC)C1=CC=C(C=C1)Cl JDCHPEZNOKLHPK-KJEAJVGRSA-N 0.000 claims 5
- -1 MEF Proteins 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 5
- 238000003556 assay Methods 0.000 claims 4
- 230000004043 responsiveness Effects 0.000 claims 4
- 230000035945 sensitivity Effects 0.000 claims 4
- IDKAKZRYYDCJDU-AEPXTFJPSA-N (2'r,3r,3's,5's)-6-chloro-3'-(3-chloro-2-fluorophenyl)-5'-(2,2-dimethylpropyl)-n-(4-hydroxycyclohexyl)-2-oxospiro[1h-indole-3,4'-pyrrolidine]-2'-carboxamide Chemical compound C1([C@H]2[C@@H](N[C@H]([C@]22C3=CC=C(Cl)C=C3NC2=O)CC(C)(C)C)C(=O)NC2CCC(O)CC2)=CC=CC(Cl)=C1F IDKAKZRYYDCJDU-AEPXTFJPSA-N 0.000 claims 3
- TVTXCJFHQKSQQM-LJQIRTBHSA-N 4-[[(2r,3s,4r,5s)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)pyrrolidine-2-carbonyl]amino]-3-methoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1NC(=O)[C@H]1[C@H](C=2C(=C(Cl)C=CC=2)F)[C@@](C#N)(C=2C(=CC(Cl)=CC=2)F)[C@H](CC(C)(C)C)N1 TVTXCJFHQKSQQM-LJQIRTBHSA-N 0.000 claims 3
- 101150008921 Brca2 gene Proteins 0.000 claims 3
- YJCZPJQGFSSFOL-MNZPCBJKSA-N CCN1[C@H]([C@H](C2=CC=CC(Cl)=C2F)[C@]2(C(=O)NC3=CC(Cl)=CC=C23)C11CCCCC1)C(=O)NC12CCC(CC1)(CC2)C(O)=O Chemical compound CCN1[C@H]([C@H](C2=CC=CC(Cl)=C2F)[C@]2(C(=O)NC3=CC(Cl)=CC=C23)C11CCCCC1)C(=O)NC12CCC(CC1)(CC2)C(O)=O YJCZPJQGFSSFOL-MNZPCBJKSA-N 0.000 claims 3
- 102100024457 Cyclin-dependent kinase 9 Human genes 0.000 claims 3
- 101100193633 Danio rerio rag2 gene Proteins 0.000 claims 3
- 101150106966 FOXO1 gene Proteins 0.000 claims 3
- 101000980930 Homo sapiens Cyclin-dependent kinase 9 Proteins 0.000 claims 3
- 101150024075 Mapk1 gene Proteins 0.000 claims 3
- 101710143112 Mothers against decapentaplegic homolog 4 Proteins 0.000 claims 3
- 102100025725 Mothers against decapentaplegic homolog 4 Human genes 0.000 claims 3
- 101100193635 Mus musculus Rag2 gene Proteins 0.000 claims 3
- 101100208706 Mus musculus Usp18 gene Proteins 0.000 claims 3
- 101100095907 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SLT2 gene Proteins 0.000 claims 3
- 101100345685 Xenopus laevis mapk1 gene Proteins 0.000 claims 3
- 229940125904 compound 1 Drugs 0.000 claims 3
- 238000001514 detection method Methods 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- AGBSXNCBIWWLHD-FQEVSTJZSA-N siremadlin Chemical compound COC1=NC(OC)=NC=C1C(N1C(C)C)=NC2=C1[C@H](C=1C=CC(Cl)=CC=1)N(C=1C(N(C)C=C(Cl)C=1)=O)C2=O AGBSXNCBIWWLHD-FQEVSTJZSA-N 0.000 claims 3
- VDLGAZDAHPLOIR-VAZUXJHFSA-N sulanemadlin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@]2(C)CCCCCC\C=C\CCC[C@](C)(NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC3=CNC4=CC=CC=C34)NC(=O)[C@H](CC5=CC=C(O)C=C5)NC(=O)[C@H](CCC(O)=O)NC2=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(N)=O VDLGAZDAHPLOIR-VAZUXJHFSA-N 0.000 claims 3
- 108010014778 ATSP-7041 Proteins 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 102000003952 Caspase 3 Human genes 0.000 claims 2
- 108090000397 Caspase 3 Proteins 0.000 claims 2
- 102000003910 Cyclin D Human genes 0.000 claims 2
- 108090000259 Cyclin D Proteins 0.000 claims 2
- 102000003909 Cyclin E Human genes 0.000 claims 2
- 108090000257 Cyclin E Proteins 0.000 claims 2
- 101100239628 Danio rerio myca gene Proteins 0.000 claims 2
- 238000002965 ELISA Methods 0.000 claims 2
- 101001109620 Homo sapiens Nucleolar and coiled-body phosphoprotein 1 Proteins 0.000 claims 2
- 229940083338 MDM2 inhibitor Drugs 0.000 claims 2
- 239000012819 MDM2-Inhibitor Substances 0.000 claims 2
- 101150039798 MYC gene Proteins 0.000 claims 2
- 101000762244 Mus musculus Cadherin-17 Proteins 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 101100509643 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) mcb gene Proteins 0.000 claims 2
- 102100022726 Nucleolar and coiled-body phosphoprotein 1 Human genes 0.000 claims 2
- 102000019347 Tob1 Human genes 0.000 claims 2
- 108700038377 Tob1 Proteins 0.000 claims 2
- 101150041680 Tob1 gene Proteins 0.000 claims 2
- 101100459258 Xenopus laevis myc-a gene Proteins 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- YCXOHEXZVKOGEV-DNRQZRRGSA-N 1-[6-[(4-fluorophenyl)methyl]-5-(hydroxymethyl)-3,3-dimethyl-2H-pyrrolo[3,2-b]pyridin-1-yl]-2-[(2R,5R)-5-methyl-2-[[(3R)-3-methylmorpholin-4-yl]methyl]piperazin-1-yl]ethanone Chemical group FC1=CC=C(C=C1)CC=1C=C2C(=NC1CO)C(CN2C(CN2[C@H](CN[C@@H](C2)C)CN2[C@@H](COCC2)C)=O)(C)C YCXOHEXZVKOGEV-DNRQZRRGSA-N 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 102000025171 antigen binding proteins Human genes 0.000 claims 1
- 108091000831 antigen binding proteins Proteins 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 238000003491 array Methods 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 claims 1
- 238000002967 competitive immunoassay Methods 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 238000000684 flow cytometry Methods 0.000 claims 1
- 238000003633 gene expression assay Methods 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 238000003018 immunoassay Methods 0.000 claims 1
- 238000000760 immunoelectrophoresis Methods 0.000 claims 1
- 238000010166 immunofluorescence Methods 0.000 claims 1
- 238000001114 immunoprecipitation Methods 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 238000004949 mass spectrometry Methods 0.000 claims 1
- 208000025113 myeloid leukemia Diseases 0.000 claims 1
- 238000004848 nephelometry Methods 0.000 claims 1
- 238000002203 pretreatment Methods 0.000 claims 1
- 238000003498 protein array Methods 0.000 claims 1
- 238000000159 protein binding assay Methods 0.000 claims 1
- 238000003127 radioimmunoassay Methods 0.000 claims 1
- 238000003757 reverse transcription PCR Methods 0.000 claims 1
- 230000005945 translocation Effects 0.000 claims 1
- 238000004879 turbidimetry Methods 0.000 claims 1
- 238000001262 western blot Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2013476.3A GB202013476D0 (en) | 2020-08-27 | 2020-08-27 | Cancer biomarkers |
| GB2013476.3 | 2020-08-27 | ||
| GBGB2020493.9A GB202020493D0 (en) | 2020-12-23 | 2020-12-23 | Cancer biomarkers |
| GB2020493.9 | 2020-12-23 | ||
| PCT/IB2021/057853 WO2022043930A2 (en) | 2020-08-27 | 2021-08-27 | Biomarkers for cancer therapy using mdm2 antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023539867A JP2023539867A (ja) | 2023-09-20 |
| JP2023539867A5 JP2023539867A5 (https=) | 2024-09-04 |
| JPWO2022043930A5 true JPWO2022043930A5 (https=) | 2024-09-04 |
Family
ID=77595601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023513510A Pending JP2023539867A (ja) | 2020-08-27 | 2021-08-27 | Ｍｄｍ２アンタゴニストを用いた癌治療に関するバイオマーカー |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230313313A1 (https=) |
| EP (1) | EP4204812A2 (https=) |
| JP (1) | JP2023539867A (https=) |
| KR (1) | KR20230058124A (https=) |
| CN (1) | CN116194088A (https=) |
| AU (1) | AU2021333983A1 (https=) |
| CA (1) | CA3181715A1 (https=) |
| TW (1) | TW202214248A (https=) |
| WO (1) | WO2022043930A2 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201517217D0 (en) | 2015-09-29 | 2015-11-11 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
| GB201704965D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| CN112022812B (zh) * | 2020-11-03 | 2021-01-29 | 上海亚盛医药科技有限公司 | 一种包含杂环类化合物的组合物、其制备方法和应用 |
| CN114796227B (zh) * | 2022-05-30 | 2023-12-01 | 中山大学 | Ponatinib在制备预防或治疗血管退行性疾病药物中的应用及该药物 |
| WO2024097876A1 (en) * | 2022-11-02 | 2024-05-10 | Board Of Regents, The University Of Texas System | Methods relating to optimizing therapy selection for acute myeloid leukemia |
| TW202539630A (zh) * | 2023-11-16 | 2025-10-16 | 日商大塚製藥股份有限公司 | 包括ｍｄｍ２－ｐ５３抑制劑之醫藥組成物 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| WO1998004689A1 (en) | 1995-07-31 | 1998-02-05 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
| US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
| WO2000075184A1 (en) * | 1999-06-04 | 2000-12-14 | Yale University | Modulation of protein levels using the scf complex |
| KR20120099462A (ko) | 2009-11-12 | 2012-09-10 | 더 리젠츠 오브 더 유니버시티 오브 미시건 | 스피로-옥신돌 ｍｄｍ2 길항제 |
| US8088815B2 (en) | 2009-12-02 | 2012-01-03 | Hoffman-La Roche Inc. | Spiroindolinone pyrrolidines |
| US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
| JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| US8815926B2 (en) | 2012-01-26 | 2014-08-26 | Novartis Ag | Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases |
| SI2958893T1 (sl) | 2013-02-21 | 2017-08-31 | F. Hoffmann-La Roche Ag | Asimetrična sinteza substituiranega pirolidin-2-karboksamida |
| CN105358530A (zh) | 2013-06-10 | 2016-02-24 | 美国安进公司 | 制备mdm2抑制剂的方法及其结晶形式 |
| EP3013316B1 (en) | 2013-06-24 | 2018-05-30 | F.Hoffmann-La Roche Ag | Stable intravenous formulation |
| BR112015031542A2 (pt) * | 2013-07-03 | 2017-07-25 | Hoffmann La Roche | métodos de previsão de reação de pacientes com câncer, método de tratamento de câncer, kit de previsão da reação ao tratamento e processos, métodos e usos inovadores |
| KR102272536B1 (ko) | 2013-09-04 | 2021-07-02 | 다이이찌 산쿄 가부시키가이샤 | 스피로옥시인돌 유도체의 제조 방법 |
| ES2883289T3 (es) | 2013-12-20 | 2021-12-07 | Astex Therapeutics Ltd | Compuestos heterocíclicos bicíclicos y sus usos en terapia |
| ES2712973T3 (es) | 2014-04-17 | 2019-05-17 | Univ Michigan Regents | Inhibidores de MDM2 y métodos terapéuticos que usan los mismos |
| WO2016059241A2 (en) * | 2014-10-17 | 2016-04-21 | Biomirna Holdings Ltd. | Lung cancer diagnostics and therapeutics with mir-660 |
| GB201517216D0 (en) | 2015-09-29 | 2015-11-11 | Cancer Res Technology Ltd And Astex Therapeutics Ltd | Pharmaceutical compounds |
| GB201517217D0 (en) | 2015-09-29 | 2015-11-11 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
| AU2017246452C1 (en) | 2016-04-06 | 2021-06-03 | The Regents Of The University Of Michigan | MDM2 protein degraders |
| WO2017176958A1 (en) | 2016-04-06 | 2017-10-12 | The Regents Of The University Of Michigan | Monofunctional intermediates for ligand-dependent target protein degradation |
| WO2017205786A1 (en) | 2016-05-27 | 2017-11-30 | Aileron Therapeutics, Inc. | Cell permeable peptidomimetic macrocycles |
| GB201704965D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| GB201919219D0 (en) | 2019-12-23 | 2020-02-05 | Otsuka Pharma Co Ltd | Cancer biomarkers |
-
2021
- 2021-08-27 CA CA3181715A patent/CA3181715A1/en active Pending
- 2021-08-27 JP JP2023513510A patent/JP2023539867A/ja active Pending
- 2021-08-27 TW TW110131860A patent/TW202214248A/zh unknown
- 2021-08-27 AU AU2021333983A patent/AU2021333983A1/en active Pending
- 2021-08-27 EP EP21763416.1A patent/EP4204812A2/en active Pending
- 2021-08-27 US US18/042,167 patent/US20230313313A1/en active Pending
- 2021-08-27 WO PCT/IB2021/057853 patent/WO2022043930A2/en not_active Ceased
- 2021-08-27 CN CN202180050903.9A patent/CN116194088A/zh active Pending
- 2021-08-27 KR KR1020237010334A patent/KR20230058124A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zamanova et al. | Carbonic anhydrases as disease markers | |
| Rho et al. | Protein and glycomic plasma markers for early detection of adenoma and colon cancer | |
| Vermeire et al. | The role of C-reactive protein as an inflammatory marker in gastrointestinal diseases | |
| JP5559056B2 (ja) | ガンの診断、予測、および予後試験 | |
| JP6983221B2 (ja) | 大腸癌の併用検査 | |
| WO2004055519A2 (en) | Specific markers for pancreatic cancer | |
| JP2025111438A (ja) | イルジンおよびバイオマーカーを使用した固形腫瘍癌の治療方法 | |
| US20140315732A1 (en) | Cancer diagnosis and treatment | |
| Lee et al. | Clinical proteomics identifies urinary CD14 as a potential biomarker for diagnosis of stable coronary artery disease | |
| JP2021523379A5 (https=) | ||
| Lipshitz et al. | Emerging markers of cancer cachexia and their relationship to sarcopenia | |
| JP2018529931A5 (https=) | ||
| TWI429752B (zh) | 不健康細胞之偵測方法及其應用 | |
| Wang et al. | Combined analysis of serum SAP and PRSS2 for the differential diagnosis of CD and UC | |
| CA2830562A1 (en) | Mucin 5b as a pancreatic cyst fluid specific biomarker for accurate diagnosis of mucinous cysts and other markers useful for detection of pancreatic malignancy | |
| Manolakis et al. | α2-Heremans-schmid glycoprotein (fetuin A) downregulation and its utility in inflammatory bowel disease | |
| JPWO2022043930A5 (https=) | ||
| JP2014505251A (ja) | Ｂｃｌ−２様タンパク質１１のＳＲＭ／ＭＲＭアッセイ | |
| CN108369233A (zh) | 基于标志物人附睾蛋白4(he4)检测肺腺癌的复发的方法及相关用途 | |
| Kusamura et al. | Expression of p53, c-erbB-2, Ki-67, and CD34 in granulosa cell tumor of the ovary | |
| Tian et al. | Plasma CXCL14 as a candidate biomarker for the diagnosis of lung cancer | |
| Szymczak et al. | Identification of Candidate Inflammatory-Nutritional Blood Biomarkers for Cachexia and Muscle Depletion in Polish Chronic Heart Failure Patients | |
| KR101913199B1 (ko) | 파브리병 진단용 바이오마커 및 이의 용도 | |
| US11578370B2 (en) | Methods for diagnosis and treatment of patients having solid tumors | |
| Guedes et al. | Evaluating DNA Damage in Peripheral Blood Lymphocytes: A Promising Biomarker for Diagnosis, Prognosis and Treatment Monitoring in Colorectal Cancer |